US EditionKeymed Biosciences Announces Approval of IND for CM518D1 by the National Medical Products Administration of China for the Treatment of Gastrointestinal Cancers
- Keymed Biosciences announced CM518D1 received Investigational New Drug approval from China's NMPA on April 24, 2025.
- This CDH17-targeted therapy addresses a protein highly expressed in gastrointestinal cancers driving tumor invasion.
- CM518D1 delivers payloads with a specific antibody and showed efficacy and safety in preclinical studies.
- Keymed, listed as HKEX: 02162, uses its ADC platform to develop therapies for unmet needs.
- This approval advances Keymed's pipeline, offering a potential treatment for advanced solid tumors.
Insights by Ground AI
Does this summary seem wrong?
41 Articles
41 Articles
All
Left
2
Center
14
Right
2
The Daily Advance+40 Reposted by 40 other sources
Keymed Biosciences Announces Approval of IND for CM518D1 by the National Medical Products Administration of China for the Treatment of Gastrointestinal Cancers
CHENGDU, China, April 24, 2025 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) ("Keymed" or the "Company") recently announced CM518D1, a CDH17-targeted antibody-drug conjugate (ADC) developed by Keymed, received Investigational New Drug (IND) approval from the Center for Drug Evaluation (CDE)…
Coverage Details
Total News Sources41
Leaning Left2Leaning Right2Center14Last UpdatedBias Distribution78% Center
Bias Distribution
- 78% of the sources are Center
78% Center
11%
C 78%
11%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
